Rizatriptan Wafer–Sublingual vs. Placebo at the Onset of Acute Migraine
2000; SAGE Publishing; Volume: 20; Issue: 6 Linguagem: Inglês
10.1046/j.1468-2982.2000.00079.x
ISSN1468-2982
AutoresJ. A. Klapper, Simon O’Connor,
Tópico(s)Dental Anxiety and Anesthesia Techniques
ResumoRizatriptan wafer is a 5HT 1B/1D agonist for use in the acute treatment of migraine. It is a freeze-fried formulation, approved for oral administration, which dissolves on the tongue and is swallowed with saliva. In this study the efficacy of sublingually administered rizatriptan 10-mg wafer was evaluated in a randomized, double-blind, placebo-controlled, out-patient study involving 39 migraineurs. Patients were instructed to treat a migraine at the onset of pain in order to evaluate time of onset of pain relief and pain relief at 1 h. The average time to onset of relief was 25 min for patients treated with rizatriptan wafer and 27 min for patients treated with placebo. At 1 h, 50% of the patients receiving rizatriptan wafer and 50% of the patients receiving placebo experienced significant relief. Implications and potential reasons for a high placebo response are discussed.
Referência(s)